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Previous gestational diabetes mellitus (pGDM) indicates future risk for type 2 diabetes (T2DM). Insulin resistance (IR)
may precede T2DM in many years and is associated with an increased risk for cardiovascular diseases.
Aim: This study aims to identify endothelial dysfunction and cardiovascular risk factors in women with pGDM.
Methods: This cross-sectional analysis included 45 non diabetic women, 20 pGDM and 25 controls, at least one
year after delivery. Body mass index (BMI), abdominal circumference (AC), blood pressure, serum lipids, liver enzymes,
uric acid, nonesterified fatty acids, C-reactive protein and plasma glucose, insulin, fibrinogen and plasminogen activator
inhibitor 1 were measured. HOMA IR and β were calculated. Pre and post induced ischemia videocapillaroscopy was
performed in hand nailfold to evaluate microvascular morphologic aspect and functional response.
Results: AC and fasting glucose were significantly higher in pGDM (p = 0.01 and p = 0.002 respectively). Women with
pGDM and BMI < 25 kg/m2 had significantly higher levels of fasting insulin and HOMA IR than controls (p = 0.008 and
0.05 respectively). Abnormal morphologic findings were more frequent and papillae rectification were 3.3 times more
prevalent in pGDM (p = 0.003). Other microvascular parameters did not differ between groups.
Conclusion: Cardiovascular risk factors and a microcirculation abnormality (papillae rectification) were significantly
increased in young non-diabetic women with pGDM.
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Gestational diabetes mellitus (GDM) is a heterogeneous
disorder defined as glucose intolerance first recognized
during pregnancy [1]. This metabolic abnormality usu-
ally resolves immediately post partum, but implies in a
higher risk of future type 2 diabetes mellitus (T2DM). In
the vast majority of cases, the pathogenesis of GDM re-
sembles that of T2DM. In both conditions, the β cell re-
serve is unable to counterbalance the insulin resistance.
During pregnancy, this increased demand is caused by
placental hormones. It has been suggested that GDM
and T2DM should be taken as one single entity, al-
though clinically evident in different lifetime periods [2].* Correspondence: lenitazaj@gmail.com
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article, unless otherwise stated.T2DM is a known risk factor for cardiovascular dis-
ease (CVD) and insulin resistance (IR) has been impli-
cated in this association [3]. The mechanisms involved
in this link are multiple and complex. Chronic hypergly-
cemia may directly participate in the development of
CVD [4] and other conditions frequently seen in patients
with T2DM may also contribute to the increased risk, such
as hypertension, dyslipidemia, altered fibrinolysis and obes-
ity [5, 6]. Endothelial dysfunction and chronic sub-clinical
or low-grade inflammation are closely associated with
obesity and insulin resistance and could be involved in the
pathogenesis of T2DM and CVD. Increased levels of acute
phase proteins such as C-reactive protein (CRP), inter-
leukin 6 (IL6) and sialic acid have been shown in pa-
tients with T2DM and insulin resistance [7,8] and are
known to be associated with CVD [8–11]. This low-grade
chronic inflammation at the level of the vessel walltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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flection of endothelial dysfunction. Capillary morphological
and functional abnormalities have also been described in
patients with T2DM during videocapillaroscopy (VC)
[12-14], due to endothelial dysfunction, increased plasma
viscosity, autonomic neuropathy and high vascular perme-
ability [15,16].
Groups at risk for T2DM such as women with pGDM
usually have more insulin resistance than the healthy
general population, which can start many years before
the appearance of any derangement in glucose homeo-
stasis [17,18]. Beta cell dysfunction is also important for
the development of T2DM in these individuals [18].
Ryan et al. have shown that women with previous GDM
even with normal post-pregnancy oral glucose tolerance
test (OGTT) had both insulin secretion and action de-
fects in the post-conception period [19], although T2DM
usually develops only years after pregnancy in this popu-
lation. Therefore, this group might be considered in a
very early stage of the natural history of T2DM and may
offer a unique opportunity of studying abnormalities that
appear early in the process.
It is still unclear how early a higher CVD risk appears
in the natural history of T2DM. Women with previous
GDM (pGDM) and a normal post-pregnancy OGTTalready
have a higher risk than the general population [20]. Endo-
thelial dysfunction and sub-clinical inflammation have
often been reported in individuals at risk for T2DM in
general, which would contribute to the development of
CVD [6]. In the specific subgroup of women with pGDM,
few and contrasting data have reported vascular endo-
thelial dysfunction and increased serum levels of inflam-
matory markers. Insulin resistance itself and increased
abdominal fat could be implicated in these phenomena,
although the possibility of a specific genetically deter-
mined vascular derangement has also been suggested
[9,11,21-24]. The aim of this study was to identify cardio-
vascular risk factors and microvascular abnormalities diag-
nosed through videocapillaroscopy in apparently healthy
women with pGDM from a multi-ethnic population.
Patients and methods
We have performed a cross-sectional analysis of cardio-
vascular risk factors and endothelial function in women
with pGDM and those with a past history of normal
glucose tolerance during pregnancy. The protocol was
approved by the Local Ethics Committee and informed
consent was obtained from all subjects. Ninety six women
who had the diagnosis of GDM between 24 and 30th week
of pregnancy at least 1 year before the study were invited
to participate. The diagnosis of GDM was established with
a 2 step- protocol according to the previous ADA criteria
[1]. All patients were followed during and after pregnancy
by the same medical team in the Diabetes and Pregnancyoutpatient unit of Maternidade Escola da Universidade
Federal do Rio de Janeiro. Women with T2DM, impaired
fasting glucose or glucose intolerance according to OMS
criteria [25], current pregnancy, menopause, use of vaso-
active, antilipemic or antidiabetics drugs, vascular, kidney,
liver, dermatological and infectious diseases were excluded
from the analysis. From the 37 women with pGDM that
accepted to participate, 20 were included. Twenty five healthy
women selected in the same outpatient unit who had de-
livered 1 year or more before the study without pGDM,
history of fetal macrosomia, menopause, use of vasoactive
or antilipemic drugs and arterial hypertension were in-
cluded as controls.
Maternal age in the labor, weight before pregnancy
and in the third trimester, parity and previous abortions
history were obtained in the medical charts; family his-
tory of diabetes, educational status, ethnic group, height,
current weight, abdominal circumference and blood
pressure were registered. Fasting capillary blood glucose
(12–14 hours) was measured and subjects with results ≥
140 mg/dl were excluded. All other patients underwent
a 75 grams 2 hour oral glucose tolerance test. Serum cre-
atinine, whole and HDL cholesterol, tryglicerides, liver
enzymes, uric acid, nonesterified fatty acids, C-reactive
protein and plasma insulin, fibrinogen and plasminogen
activator inhibitor 1 were measured. Plasma insulin was
measured with a fluoroimmunoassay (Auto Delfia kit, Turku,
Finland). NEFA were measured with an enzymatic method
(Wako, Richmond, VA); normal range in fasting state:
0.09-0.6 mmol/l). PAI-1 was measured with a Chromolize
assay (Biopool International,Ventura, CA) wich reference
interval for subjects between 20 to 49 years old was < 14.4
U/ml. Homeostasis model assessment (HOMA) IR and β
were calculated. It was applied a logarithmic function of
the HOMAβ in order to get a normal distribution of those
values.
VC was performed in rest condition and during post-
occlusive reactivity test and images were processed in a
computer (Pentium 2 Microsoft). VC was done under con-
trolled temperature environment (24–26°C) using micro-
scope Wild Leitz GLS 100, videocamera COHU 8215, VCR
and TV Sony 29-inch. Post-occlusive reactive hyperemia
was performed using a sphygmomanometer attached to the
fourth left hand finger, 20 mmHg above maximum arterial
pressure during 1 min. Images were captured by a com-
puter Pentium 1 (Microsoft) through Scanpro 3 software,
each 2 s, during 1 min after releasing pressure. Measures
were determined through Scanpro 3 software by at least
two investigators blind to clinical data and in two different
moments by each investigator to establish the concordance
(k > 0.6 in both). A perpendicular line tangent to internal
limit of a capillary loop transverse segment defined the
transverse segment area (TSA) to be measured as shown in
Figure 1. Zero time point after ischemia was considered
Figure 1 Determination of the capillary transverse segment area.
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porary minimum hand movement could not be prevented,
blurring the image area and leading to higher surface
values. In those circumstances, those measures were not
included for the purposes of the work. Basal area of trans-
verse segment of the capillary (ATSb), maximum area of
the transverse segment of the capillary(ATSm) obtained ≥
60 seconds after the occlusion, time to get the maximum
post-ischemia area (MAIt) and the maximum increment
percent (MAIp) from basal measurement were deter-
mined in patients with pGDM and controls. The following
morphologic microvascular abnormalities were also in-
vestigated through the evaluation of the recorded basal
images by two independent examiners: granular flow
(clumps of red blood cells inside the capillary), disor-
dered distribution of loops (when the disposition of the
capillary loops was not positioned parallel to the edge of
the nail, as a fence), loops of aberrant format (with the
aspect of a hair clip with tortuous efferent and recti-
linear afferent branches), short loops (when there was
an area of edema partially erasing the branches), micro-
ectasy (saccular dilation in the capillary branches), papillae
rectification (erasure or fusion of two or more papillae),
tortuous transverse segment and enlarged transverse seg-
ment. The transverse segment unites the afferent and the
efferent branches of the capillary loop. Tortuosity was de-
fined as the presence of spiral movement and capillary
distention.
For the statistical analysis, Mann Whitney U and Fisher
exact tests were used to compare data between groups.
Spearman correlation was used to test for association be-
tween continuous variables. All tests were two-tailed, with
α = 0.05 for the main hypothesis.Results
Clinical evaluation
The study group comprised 45 women, 20 with pGDM and
25 controls, who were evaluated 43.26 ± 29.17 months after
the delivery, in average (range: 12–144). Their main charac-
teristics are shown in Table 1. Groups were similar in age,
number of previous pregnancies, ethnicity and number of
school years. No differences were found among eight
women in use of oral contraceptives (five in pGDM and
three in controls), when studied separately. Two women in
each group were smokers and all denied alcohol consume.
A family history of T2DM (in first degree relatives) did
not differ between groups (45% vs 48%; p = 1.0). There
were also no significant differences between groups in
the blood pressure or the body mass index (BMI), as
seen in Table 1. Two women with pGDM reported a
previous history of hypertension and one used hydro-
chlorothyazide irregularly. In control group, only one
woman had history of hypertension with no specific
treatment. A higher abdominal circumference (AC) was
observed in pGDM when compared to controls (102.3 ±
16.3 cm vs 91.2 ± 16.2 cm; p = 0.01) and AC > 88 cm was
twice more common in the former than the latter. There
was a correlation between AC values and weight gain
after the index pregnancy (r = 0.53; confidence interval:
0.09-0.8; p = 0.018), but not with weight gain during
pregnancy (r = −0.3; IC:-0.67-0.19; p = 0.21). Women
with pGDM had a tendency towards lower HDL levels
(46. 5 ± 11.4 vs 53.6 ± 11.0 mg/dl; p = 0.06) than others.
Uric acid levels, transaminases, total and LDL choles-
terol, triglycerides, free fatty acids (FFA), CRP, fibrinogen
and PAI-1 levels did not differ between groups. These
results are shown in Table 2.






Mean age (in years) 33.5 (4.9) 33.3 (6.7) 0.93
Ethnicity 0.37
Whites 8 (40%) 14 (56%)
Non-whites 12 (60%) 11 (44%)
Educational level (years) 9.4 (3.1) 10.5 (4.4) 0.50
Mean number of labors 2.0 (0.99) 2.1 (1.1) 0.96
Mean number of pregnancies 2.3 (1.22) 2.4 (1.4) 0.99
Age at conception (years) 31.3 (4.3) 29.1 (6.4) 0.17
Nursing period (months) 17.7 (15.6) 14.3 (12.1) 0.49
Body mass index 29.7 (5.9) Kg/m2 26.5 (6.19) Kg/m2 0.13
Abdominal circumference (AC) 102.3 (16.3) cm 91.2 (16.2) cm 0.01
Systolic blood pressure 114.5 (17.9) mmHg 110.8 (16.5) mmHg 0.60
Diastolic blood pressure 76.5 (11.8) mmHg 72.8 (12.0) mmHg 0.28
N 25 20
SD = Standard deviation.
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cemia (FG) (83.2 ± 13.0 vs 71.6 ± 9.4 mg/dl; p = 0.002)
than others. Parity was correlated with levels of FG (r =
0.45; confidence interval: 0.03-0.75; p = 0.04). HOMA IR
was higher in pGDM than in controls (p = 0.03), espe-
cially in the subgroup with normal BMI (p = 0.008) and
AC < 88 cm (p = 0.009), as seen in Table 3. There was a






Mean fasting glucose 83.2 (13.0) mg/dl 71.6 (9.4) mg/dl 0.002
Creatinine 0.72 (0.1) mg/dl 0.67 (0.1) mg/dl 0.14
AST 24.4 (5.2) U/l 24.9 (4.9) U/l 0.71
ALT 35.6 (7.8) U/l 40.8 (13.6) U/l 0.25
Uric acid 3.9 (0.7) mg/dl 3.7 (0.8) mg/dl 0.36
Total cholesterol 194.0 (33.8) mg/dl 185.6 (43.8) mg/dl 0.35
HDL c 46.5 (11.4) mg/dl 53.6 (11.0) mg/dl 0.06
LDL c 130.0 (32.3) mg/dl 114.3 (34.9) mg/dl 0.10
Triglycerides 87.0 (38.1) mg/dl 88.1 (63.1) mg/dl 0.44
FFA 0.47 (0.19) mmol/l 0.55 (0.23) mmol/l 0.21
CPR 0.34 (0.23) mg/dl 0.40 (0.49) mg/dl 0.50
Fibrinogen 279.5 (58.7) mg/dl 297.1 (84.7) mg/dl 0.50
PAI-1 12.1 (9.6) U/ml 16.0 (12.0) U/ml 0.25
N 25 20
SD: Standard deviation; AST : Aspartate aminotransferase; ALT: alanine
aminotransferase; HDL: High density lipoprotein; cLDL: Low density
lipoprotein, c FFA: free fatty acids, CPR: C-reactive protein, PAI-1: plasminogen
activator inhibitor-1.and FG (R = 0.54; IC: 0.29-0.72; p = 0.0001). No correla-
tions were found between HOMA IR and parity (p = 0.43),
weight gain during pregnancy (p = 0.94) or weight vari-
ation after labor (p = 0.75).
Videocapillaroscopy
VC could not be done in 5 subjects (4 pGDM and 1 from
control group) due to technical limitations of the method.
In basal videocapillaroscopy, there was significant differ-
ence between groups in the presence of papillae rectifi-
cation (68.7% vs. 20.8%, p = 0.003). Abnormal capillary
morphology obtained in the basal VC is shown in Table 4.
In the dynamic VC, no differences were identified between
the groups (Table 5).
Discussion
This study intended to investigate possible CVD risk
factors and microvascular abnormalities diagnosed through
VC in women with pGDM and normal OGTT, when
compared to a control group. Several interesting findings
were seen. First, BMI did not differ between groups, but a
higher AC was observed in those with pGDM than in con-
trols. Verma et al. also reported similar BMI in women
with and without pGDM from six to ten years after the
delivery, despite higher BMI observed in pGDM in the
fourth and fifth years after pregnancy [26]. In our study
group, the lack of difference was observed in individuals
tested 43.26 months, in average, after their labor. We
found a correlation between AC and weight gain after but
not during pregnancy. This finding may represent changes
in fat distribution associated with the aging process or par-
ity. A limitation in this study is the inability to determine if
Table 3 HOMA measurements
VARIABLE Mean/median (SD) Previous GDM (Group 1) Controls (Group 2) P value
HOMA IR
Total 2.15/1.71 (2.22) 1.23/1.04 (0.82) 0.03
BMI < 25 1.59/1.73 (0.54) 0.72/0.77 (0.35) 0.008
BMI≥ 25 2.33/1.69 (2.54) 1.64/1.51 (0.87) 0.81
AC < 88 cm 1.59/1.73 (0.54) 0.77/0.77 (0.39) 0.009
AC≥ 88 cm 2.27/1.67 (2.55) 1.22/1.06 (0.75) 0.08
LogHOMAβ
Total 2.81/2.32 (0.44) 2.23/2.16 (0.44) 0.72
BMI < 25 2.08/1.82 (0.45) 2.02/1.93 (0.44) 0.91
BMI≥ 25 2.34/2.38 (0.43) 2.39/2.32 (0.58) 0.77
N 25 20
SD-Standard deviation; BMI-body mass index AC- abdominal circumference.
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pregnancy. Branchtein L et al. have shown a significant
correlation between AC and glycemic levels in the OGTT
in 1025 women evaluated between 21th and 28th weeks of
pregnancy [27].
FG were higher in subjects with pGDM than others,
which was more evident in those with normal BMI and
AC < 88 cm. Similar differences in FG were observed
previously [18,28–30]. There is evidence that higher FG
levels, even within the normal range, may represent a
marker of increased risk for CVD. Pallardo F et al. have
reported an association between central obesity, triglyc-
erides levels and arterial blood pressure with FG but not
with glucose intolerance [31]. HOMA IR was also higher
in women with pGDM than others, indicating that this
condition is associated with increased insulin resistance,
even in the absence of OGTT abnormalities. This finding
was more striking in individuals with normal BMI,
which leads us to believe that insulin resistance in this
group occurs independently of the presence of over-




Disordered distribution of loops 12, 5
Loops with aberrant form 32
Short loops 25
Tortuous transverse segment 31, 2
Enlarged transverse segment 50
Microectasy 37, 5
Papillae rectification 68, 7
N 24
HR- Hazard ratio.and parity, weight gain during pregnancy or weight vari-
ation after labor. This may indicate that insulin resistance
precedes these environmental factors possibly associated
with metabolic abnormalities. No differences between
groups were found in the HOMAβ, what suggests
that β cell dysfunction actually develops later in the
natural history of T2DM. Abnormalities in insulin sensi-
tivity but not secretion in pGDM women have been
shown before [28,32].
No significant differences in the lipid profile were seen
between groups, except for a tendency towards lower
levels of HDL in those with pGDM, when compared to
controls. Low levels of HDL are not only markers of insu-
lin resistance, but may also of a lack of anti-atherogenic
effects [33]. We cannot exclude that the lack of differences
between groups in free fatty acid (FFA) levels may be due
to the fact that only a basal measurement was performed.
Indeed, Kousta E et al. did not find differences in basal
FFA levels between women with pGDM and controls, but
the former exhibited lower suppression of FFA than the





62, 5 0.60 (0.16-2.16) 0,52
0 8.44 (0.37- 188.63) 0,15
20, 9 1.72 (0.40- 7.32) 0,48
4, 2 7.66 (0.76-76.49) 0,13
16, 6 2.27 (0.50- 10.25) 0,44
29, 1 2.42 (0.65- 9.06) 0,20
12, 5 4.20 (0.86- 20.34) 0,11
20, 8 8.36 (1.97- 35.47) 0,003
19
Table 5 Basal and dynamic videocapillaroscopy results
Test Previous GDM Controls P value
ATSb (μ2) 382,58 (239.5–548.89) 420.9 (238–762.2) p = 0.24
ATSm (μ2) 566.8 (335–824) 646,49 (339–1124.3) p = 0.15
MAIt (seconds) 7 (2–12) 6 (2–10) p = 0.71
MAIp (%) 48.1 (33.3–69.25) 50.91 (36–77.3) p = 0.28
N 24 19
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despite being currently free from metabolic abnormal-
ities, have higher values of markers of endothelial dys-
function, such as E-selectin and intercellular adhesion
molecule 1 or ICAM-1 [35], but there is not a consen-
sus. Higher levels of CRP and sialic acid, both markers
of chronic low-grade inflammation, were also reported
in women with pGDM [28,36,37]. In our study, similar
levels of CRP were found in both groups and in all
women this marker was within the normal range. No
association was found between CRP and BMI, which
might be due to the low variation of CRP levels in the
whole sample, as the association between CRP and obes-
ity has been shown before [38]. Kim et al. also found no
differences in CRP and other inflammatory markers (fer-
ritin and leucocyte count) among women with or with-
out previous GDM [39].
Differently from Heittritter et al., who have shown
higher levels of PAI-1 in women with pGDM, we did not
see any difference between groups nor any association be-
tween this marker with BMI or AC. Although these results
might be due to the small sample size, other hypothesis to
explain this finding would be the multiethnic nature of
our study group. Solano MP et al. detected differences in
the association of PAI 1 and insulin resistance markers in
women from different ethnic backgrounds. In that ana-
lysis, Afro-descendants women did not show any associ-
ation between PAI-1 and visceral adiposity [40].
Fibrinogen levels did not differ between groups and
95% of the subjects had normal levels of this marker. Di
Bennedetto et al., on the other hand, found higher levels
of fibrinogen in individuals with pGDM than controls
[36]. It is still unclear if fibrinogen is implicated in the
pathogenesis of CVD or is a marker that reflects its ap-
pearance, but our data suggests that its raise is not an
early marker of insulin resistance.
VC has shown a higher number of papillae rectifica-
tion in the nail capillary bed in women with pGDM than
others. Papillae rectification, disordered distribution and
shortening of capillary loops were approximately 8 times
more prevalent and presence of microectasias was 4
times more prevalent in women with pGDM. Hofstee et
all recently show that all quantitative and certain quali-
tative parameters are highly reliable in terms of inter-
and intra-observer agreement in VC [41].The increase in capillary permeability is the first ab-
normality in diabetic microangiopathy. Abnormalities in
the shape of the papillae, shortening of capillary loops
and edema are markers of increased capillary permeabil-
ity [42]. Microectasia is a later finding, associated with
ischemia and endothelial cell damage in the capillary
wall [43]. To our knowledge, this is the first study to
identify VC abnormalities in women with pGDM. The
prevalence of morphologic abnormalities in women with
pGDM in our study group was slightly higher than that
described by Halfoun et al. in healthy first degree rela-
tives of patients with T2DM [16]. This emphasizes the
importance of this finding as an early microvascular al-
teration in this population at risk for T2DM. A few au-
thors have also shown early microvascular abnormalities
in women with pGDM. Shannon et al. studied nondia-
betic women with prior GDM and showed subclinical
inflammation, hypoadiponectinemia, and early vascular
dysfunction in this population suggesting an increased risk
of developing CVD [28] . Anastasiou et al. have observed a
endothelium-dependent vasodilation in the brachial artery
[44], although a smaller study did not find any abnormality
through the same technique and in vascular reactivity in
the skin [45]. Aortic function assessed by ultrasonography
and small vessel performance assessed by iontophoresis
and laser Doppler flowmetry was also reported in these in-
dividuals. Hu et al. reported an endothelium-dependent
and -independent vasodilatation impaired response of the
microcirculation in women with pGDM group when com-
pared to controls [46]. Banerjee et al. have shown that
overweight women with disglycemia during pregnancy had
normal vascular structure and stiffness, but detectable pro-
gressively impaired endothelium-dependent function at
2 years follow-up [47].
Those early vascular abnormalities might be a result of
a “hyperglycemic legacy”. Alternatively, it is possible that
some intrinsic defects in vascular function may be oper-
ating in insulin-resistant individuals, even before OGTT
abnormalities become evident.
The absence of significant differences between groups in
some biochemical parameters and endothelial function
might be due to the characteristics of our study group,
composed by healthy young women. Caballero et al. have
shown important correlations between markers of endo-
thelial damage and age in a study group that comprised
relatives of patients with T2DM older than our subjects
studied [48].
To summarize, women with pGDM, even with normal
OGTT, have subtle yet significant differences in some
CVD risk factors when compared to others, as well as
microvascular abnormalities (papillae rectification). Al-
though most of these individuals do not develop T2DM,
they are exposed to clinical and laboratory risk factors
to CVD at a young age. These women should be given
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to decrease their risk for CVD and T2DM. Longer-term
studies are necessary to verify if a pGDM would represent
a marker of future increased cardiac morbidity and define
the role of lifestyle and/or pharmacological interventions
in these subjects.
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